It has been historically said that risk factors for scleroderma renal crisis (SRC) includes include cold exposure, steroid use, dehydration, rapid progression of skin disease, tendon friction rubs, anti-RNA polymerase III antibodies and pregnancy. A new study examines risk factor for SRC at the onset and diagnosis in systemic sclerosis patients.
Dr. John Cush RheumNow
7 years 9 months ago
Combined study of Danbio (Denmark) and ARTIS (Sweden) RA registries showed that in 8987 treatment courses of abatacept, rituximab or tocilizumab there was no difference in Serious infection rates - ranging from 4.7-8.1 SIE/100 Pt Yrs. https://t.co/JpYDeSPdpy
Dr. John Cush RheumNow
7 years 9 months ago
CDC report 5 Jan 2019: 7 million cases of influenza w/ an estimated 69,000 to 84,000 hospitalized for flu-related illness. H1N1 is the most common strain. Flu activity is widespread in 30 states https://t.co/kLsZjKDJen
QD Video - Rheumatoid with but 1 Joint
What to do when RA is controlled, except for that one joint
Short-term intervention with the very low energy diet (VLED) in psoriatic arthritis (PsA) with obesity (body mass index BMI ≥ 33 kg/m2) showed that weight loss was associated with significant positive benefits on weight and disease activity in joints, entheses and skin.
Dr. John Cush RheumNow
7 years 9 months ago
Rheumatology Year in Review : New Drugs, irAEs, Enbrel in court, Opioids, new JAKs, Hot PsA Trial, new Lupus drugs, Medical Marijuana, Expen$ive Rheum drugs, Senolytics. https://t.co/9VpM4yRGfY
Dr. John Cush RheumNow
7 years 9 months ago
QD Video on RheumNow - an HLA-B27+ patient with Iritis, Enthesitis, Diarrhea. https://t.co/LusZttdAyw
Dr. John Cush RheumNow
7 years 9 months ago
QD Video from RheumNow - The RA patients with Thrombocytopenia https://t.co/GHn6b6Z3kb
Dr. John Cush RheumNow
7 years 9 months ago
RheumNow Podcast is up - discussing Gout FDA hearing, Gout Prevalence, ULT use, obesity, BMS-Celgene merger and more. Watch here https://t.co/J5xdqGYWAu Listen on iTunes or here> https://t.co/qHAO4E9cfX
Dr. John Cush RheumNow
7 years 9 months ago
FDA AAC + DSRM advisory committee votes 19 yes, 2 no and 1 abstain on continued use of Uloric/febuxostat after reviewing CV risk in the CARES study. Await FDA decision, but Look for label changes.
Dr. John Cush RheumNow
7 years 9 months ago
QD Video - lessons from the Clinic - How to evaluate the Takayasu's arteritis patient. https://t.co/tZcOOKlcVU
Dr. John Cush RheumNow
7 years 9 months ago
“The road to hell is paved with biologic plausibility”. - Dr. Steve Nissan
Dr. John Cush RheumNow
7 years 9 months ago
Today - anuary 11, 2019: Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting to discuss Safety of Febuxostat v Allopurinol. No webcast. Here are briefing documents https://t.co/DXo3EX8u9y
The most recent analysis of National Health and Nutrition Examination Survey [NHANES] 2007-2016) data shows the prevalence of gout to be 9.3 million in the USA.
Data from 5,467 participants from NHANES 2015-2016, finds gout in 3.9% or 9.2 million US adults. This includes 5.2% [5.9 million] of men and 2.7% [3.3 million] of women with gout.
Dr. Jack Cush discusses the highlights from the past week on RheumNow.com:
